IFPMA Marks World TB Day
Ahead of March 24's World TB Day, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has confirmed the biopharma industry's commitment to the World Health Organization (WHO) drive to eradicate tuberculosis and its campaign, “Wanted: Leaders for a TB-free world”, focusing on building commitment at all levels of the community. An IFPMA press releases notes that the biopharmaceutical industry is contributing to the TB challenge with R&D measures to improve access to treatments and to find more effective, safer, all-oral regimens to treat all forms of TB, and new vaccines for adolescents and adults. There are now over 60 R&D projects for TB medicines and vaccines in the pipeline, including seven products in phase III clinical trials. Recent breakthroughs made by Johnson & Johnson and Otsuka (bedaquiline and delamanid) for the treatment of MDR-TB are illustrative of new approaches being taken by biopharma companies to make broadening sustainable and responsible access a priority. "2018 is a critical year for the global TB community", writes IFPMA, "culminating with the first ever UN High-Level Meeting on TB on September 26, 2018".
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
